Asarnow Joan Rosenbaum, Emslie Graham, Clarke Greg, Wagner Karen Dineen, Spirito Anthony, Vitiello Benedetto, Iyengar Satish, Shamseddeen Wael, Ritz Louise, Birmaher Boris, Ryan Neal, Kennard Betsy, Mayes Taryn, DeBar Lynn, McCracken James, Strober Michael, Suddath Robert, Leonard Henrietta, Porta Giovanna, Keller Martin, Brent David
Drs. Asarnow, McCracken, Strober, and Suddath are with the Department of Psychiatry, University of California-Los Angeles; Drs. Brent, Iyengar, Shamseddeen, Ryan, and Birmaher and Ms. Porta are with the University of Pittsburgh; Drs. Emslie and Kennard and Ms. Mayes are with the University of Texas Southwestern Medical Center at Dallas; Drs. Clarke and DeBar are with the Kaiser Permanente Center for Health Sciences; Dr. Wagner is with the University of Texas Medical Branch; Drs. Spirito and Keller are with the Department of Psychiatry, Brown University; Dr. Vitiello and Ms. Ritz are with the National Institute of Mental Health; and Dr. Leonard, now deceased, was formerly with Brown University.
Drs. Asarnow, McCracken, Strober, and Suddath are with the Department of Psychiatry, University of California-Los Angeles; Drs. Brent, Iyengar, Shamseddeen, Ryan, and Birmaher and Ms. Porta are with the University of Pittsburgh; Drs. Emslie and Kennard and Ms. Mayes are with the University of Texas Southwestern Medical Center at Dallas; Drs. Clarke and DeBar are with the Kaiser Permanente Center for Health Sciences; Dr. Wagner is with the University of Texas Medical Branch; Drs. Spirito and Keller are with the Department of Psychiatry, Brown University; Dr. Vitiello and Ms. Ritz are with the National Institute of Mental Health; and Dr. Leonard, now deceased, was formerly with Brown University.
J Am Acad Child Adolesc Psychiatry. 2009 Mar;48(3):330-339. doi: 10.1097/chi.0b013e3181977476.
To advance knowledge regarding strategies for treating selective serotonin reuptake inhibitor (SSRI)-resistant depression in adolescents, we conducted a randomized controlled trial evaluating alternative treatment strategies. In primary analyses, cognitive-behavioral therapy (CBT) combined with medication change was associated with higher rates of positive response to short-term (12-week) treatment than medication alone. This study examines predictors and moderators of treatment response, with the goal of informing efforts to match youths to optimal treatment strategies.
Youths who had not improved during an adequate SSRI trial (N = 334) were randomized to an alternative SSRI, an alternative SSRI plus CBT, venlafaxine, or venlafaxine plus CBT. Analyses examined predictors and moderators of treatment response.
Less severe depression, less family conflict, and absence of nonsuicidal self-injurious behavior predicted better treatment response status. Significant moderators of response to CBT + medication (combined) treatment were number of comorbid disorders and abuse history; hopelessness was marginally significant. The CBT/combined treatment superiority over medication alone was more evident among youths who had more comorbid disorders (particularly attention-deficit/hyperactivity disorder and anxiety disorders), no abuse history, and lower hopelessness. Further analyses revealed a stronger effect of combined CBT + medication treatment among youths who were older and white and had no nonsuicidal self-injurious behavior and longer prestudy pharmacotherapy.
Combined treatment with CBT and antidepressant medication may be more advantageous for adolescents whose depression is comorbid with other disorders. Given the additional costs of adding CBT to medication, consideration of moderators in clinical decision making can contribute to a more personalized and effective approach to treatment.
为了增进对青少年难治性选择性5-羟色胺再摄取抑制剂(SSRI)抑郁症治疗策略的了解,我们进行了一项随机对照试验,评估替代治疗策略。在初步分析中,认知行为疗法(CBT)联合药物更换与短期(12周)治疗的阳性反应率高于单纯药物治疗。本研究旨在探讨治疗反应的预测因素和调节因素,为青少年匹配最佳治疗策略提供依据。
在充分的SSRI试验中未改善的青少年(N = 334)被随机分配至另一种SSRI、另一种SSRI加CBT、文拉法辛或文拉法辛加CBT。分析探讨治疗反应的预测因素和调节因素。
抑郁程度较轻、家庭冲突较少以及无自杀性自伤行为预示着更好的治疗反应状态。CBT+药物(联合)治疗反应的显著调节因素是共病数量和滥用史;绝望感有边缘显著性。在共病更多(尤其是注意力缺陷多动障碍和焦虑症)、无滥用史且绝望感较低的青少年中,CBT/联合治疗相对于单纯药物治疗的优势更为明显。进一步分析显示,在年龄较大、为白人、无自杀性自伤行为且研究前药物治疗时间较长的青少年中,CBT+药物联合治疗的效果更强。
对于抑郁症合并其他疾病的青少年,CBT与抗抑郁药物联合治疗可能更具优势。鉴于在药物治疗基础上增加CBT会增加额外费用,在临床决策中考虑调节因素有助于采取更个性化、有效的治疗方法。